Long-term HPV type-specific risks for ASCUS and LSIL: A 14-year follow-up of a randomized primary HPV screening trial

International Journal of Cancer

Volumn 136, Issue 2, 2015, Pages 350-359

  Elfström, K Miriam ^a   Smelov, Vitaly ^a   Johansson, Anna L V ^a   Eklund, Carina ^a   Naucler, Pontus ^a,b   Arnheim Dahlström, Lisen ^a   Dillner, Joakim ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ASCUS; cervical cancer screening; HPV infections; HPV testing; LSIL

Indexed keywords

ABSOLUTE RISK; ADULT; ARTICLE; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; CYTOLOGY; DISEASE ASSOCIATION; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; MAJOR CLINICAL STUDY; MASS SCREENING; NONHUMAN; PAPILLOMAVIRUS INFECTION; POPULATION ATTRIBUTABLE PROPORTION; PRECANCER AND CANCER-IN-SITU; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; COMPLICATION; EARLY DIAGNOSIS; EPIDEMIOLOGY; GENETICS; INTERVENTION STUDY; ISOLATION AND PURIFICATION; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SWEDEN; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

VIRUS DNA;

ADULT; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERVENTION STUDIES; NEOPLASM GRADING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; SWEDEN; UTERINE CERVICAL NEOPLASMS;

EID: 84922288372     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28984     Document Type: Article

References (22)

1. Guan P, Howell-Jones R, Li N, et al., Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012; 131: 2349-59.
2. Bzhalava D, Guan P, Franceschi S, et al. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology 2013; 445: 224-31.
3. Trope A, Sjoborg KD, Nygard M, et al., Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds. J Clin Microbiol 2012; 50: 1927-35.
4. Safaeian M, Solomon D, Wacholder S, et al., Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. Obstet Gynecol 2007; 109: 1325-31.
5. Swedish National Quality Register for Cervical Cancer Prevention, Prevention of Cervical Cancer in Sweden: Annual Report 2013. Stockholm, Sweden: Swedish National Quality Register for Cervical Cancer Prevention, 2013.
6. Schlecht NF, Platt RW, Duarte-Franco E, et al., Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003; 95: 1336-43.
7. Canfell K, Chesson H, Kulasingam SL, et al., Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine 2012; 30 Suppl 5: F157-67.
8. Naucler P, Ryd W, Tornberg S, et al., Human papillomavirus and Papanicolaou tests to screen for cervical cancer. New Engl J Med 2007; 357: 1589-97.
9. Elfstrom KM, Smelov V, Johansson AL, et al., Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ 2014; 348: g130.
10. Jacobs MV, Snijders PJ, Voorhorst FJ, et al., Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol 1999; 52: 498-503.
11. Wahlstrom C, Iftner T, Dillner J, et al., Population-based study of screening test performance indices of three human papillomavirus DNA tests. J Med Virol 2007; 79: 1169-75.
12. Soderlund-Strand A, Carlson J, Dillner J,. Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol 2009; 47: 541-6.
13. Eklund C, Forslund O, Wallin KL, et al., The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J Clin Microbiol 2012; 50: 2289-98.
14. Eklund C, Zhou T, Dillner J,. Global proficiency study of human papillomavirus genotyping. J Clin Microbiol 2010; 48: 4147-55.
15. Elfgren K, Rylander E, Radberg T, et al., Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol 2005; 193: 650-7.
16. Rothman KJ, Greenland S., Modern epidemiology, 2nd edn. Philadelphia, PA: Lippincott Williams and Wilkins, 1998.
17. Howell LP, Davis RL,. Follow-up of Papanicolaou smears diagnosed as atypical squamous cells of undetermined significance. Diagn Cytopathol 1996; 14: 20-4.
18. Duggan MA, Brasher PM,. Accuracy of Pap tests reported as CIN I. Diagn Cytopathol 1999; 21: 129-36.
19. Wentzensen N, Schiffman M, Dunn T, et al., Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer 2009; 125: 2151-8.
20. Insinga RP, Liaw KL, Johnson LG, et al., A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008; 17: 1611-22.
21. Brismar-Wendel S, Froberg M, Hjerpe A, et al., Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions. Br J Cancer 2009; 101: 511-7.
22. Castle PE, Solomon D, Schiffman M, et al., Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005; 97: 1066-71.